Our story
XEMPERIA SA, is a science-driven startup founded in 2023 as spin-off from the University of Fribourg, Switzerland. Built on over 25 years of pioneering translational cancer research and biomarker discovery expertise.
The Team
XEMPERIA, is driven by a passionate, multidisciplinary team with complementary expertise spanning cancer biology, oncology diagnostics, biostatistics, artificial intelligence, legal affairs, and business strategy. United by a shared mission to revolutionize breast cancer care, we harness cutting-edge science and innovation to transform early detection and monitoring.
Prof. Curzio Rüegg
CEO/CSO
MD, trained in internal medicine, immunology, cell and molecular biology (Basel, Zürich, San Francisco). Chair of Pathology, UNIFR, Friburg.
PhD Sarah Cattin
CTO
PhD in Medical Sciences, UNIFR (Fribourg). Specialist in cancer biomarkers and molecular biology Extensive experience in translational studies and cell analytics.
Dr. Ivana Domljanovic
Chief Nanotechnology Officer (CNO)
PhD in Medical Sciences & Diagnostics and DNA nanotechnology. Research Associate, UNIFR, Fribourg.
Sofia Bernasconi
Communication Manager
Master’s student in Business Communication with a specialization in Ethics and Political Economy at the University of Fribourg. Responsible for the project’s communication and awareness activities.
The SAB
XEMPERIA is supported by a Scientific Advisors Board (SAB) consisting of leaders in cancer biology, cancer biomarkers, translational and clinical oncology
Prof. Klaus Pantel
Director of the Tumor Biology Institute, Universitäts Klinikum Eppendorf, Hamburg, Germany. Pioneer of the liquid biopsy field.
Prof. Suzette Delaloge
MD, Clinical oncologist, Director of the Interception medico-scientific program, Institut Gustave Roussy, (IGFR), Paris, France.
Prof. Christine Desmedt
PhD, Translational Breast Cancer, Research. Katholieke Universiteit Leuven (KLU), Leuven, Belgium.
Dr. Mauro Delorenzi
PhD, Biologist Translational Bioinformatics and Statistics. Emeritus head of Bioinformatics Core Facility (BCF) UNIL-SIB, Lausanne, Switzerland.
Prof. Olivia Pagani
MD, Clinical oncologist. Member of the International Breast Cancer Study Group (IBCSG). Emeritus head breast cancer clinic and research, IOSI, Bellinzona, Switzerland.
Prof. Christine Desmedt
PhD, Translational Breast Cancer, Research. Katholieke Universiteit Leuven (KLU), Leuven, Belgium
Interested in knowing more?
- © 2025 Xemperia. All rights reserved | Imprint | Design: ZebraZbinden | Development: FRESCHI IT